Ovid Therapeutics OVID 深 沪
已收盘 10-02 16:00:00 美东时间
2.38
-0.050
-2.06%
华盛通- 最 高2.48
- 今 开2.47
- 成交量 217.37万股
- 最 低 2.33
- 昨 收 2.43
- 总市值 4.65亿
- 52周最高 3.105
- 市盈率 静 --
- 换手率 1.11%
- 52周最低 1.18
- 委 比 -17.93%
- 总股本 1.95亿
- 历史最高 15.89
- 量 比 1.67
- 振 幅 6.17%
- 历史最低 0.2425
- 每 手 1
- 风险率 0.53%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Vail Resorts, Inventiva And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Tuesday. Shares of Vail Resorts Inc (NYSE:MTN) fell sharply in pre-market trading as the company reported mixed results for the fourth quarter. The company posted quarterly losses of $5.34 per share, which missed...
09-29 20:01
美股大行评级 | Adobe绩后获多家大行齐升目标价！最高看多至270美元；甲骨文绩后现多空分歧
今日重点评级关注：Ascendiant Capital：维持Outlook Therapeutics"买入"评级，目标价从10美元升至10.5美元；摩根士丹利：维持Aurora Innovation"超配"评级，目标价从14美元升至18美元
09-14 16:05
HC Wainwright & Co. Maintains Buy on Ovid Therapeutics, Raises Price Target to $5
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Ovid Therapeutics (NASDAQ:OVID) with a Buy and raises the price target from $4 to $5.
09-11 19:13
Ovid Therapeutics Q2 EPS $(0.08) Beats $(0.12) Estimate, Sales $733.000K Beat $30.000K Estimate
Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.12) by 27.27 percent. This is a 33.33 percent decrease over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $733.000 tho...
08-13 20:58
美股大行评级 | 潜在涨幅3586.64%！HC Wainwright上调Enlivex目标价至80美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从20美元升至80美元；Canaccord Genuity：维持Pharming Group NV Sponsored ADR"买入"评级，目标价从37美元升至38美元
08-04 11:45
Oppenheimer Maintains Outperform on Ovid Therapeutics, Raises Price Target to $9
Oppenheimer analyst Kostas Biliouris maintains Ovid Therapeutics (NASDAQ:OVID) with a Outperform and raises the price target from $7 to $9.
08-03 22:25
Ovid Therapeutics appoints Charles Carter as new CFO
Ovid Therapeutics ( ($OVID) ) has issued an announcement. On July 5, 2026, Ovid...
07-08 19:29
Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development
Ovid Therapeutics announced several key leadership appointments to strengthen its executive team. Kevin Norrett was appointed Chief Business Officer, Charles Carter promoted to Chief Financial Officer, Eliseo Salinas joined as Executive R&D Advisor, and Victoria Fort became Chief Strategy Officer. These changes aim to support the company's growth and strategic initiatives in developing innovative treatments for brain disorders.
07-08 11:00
uniQure's Experimental Drug Shows Early Promise In Difficult-To-Treat Epilepsy
uniQure N.V. (NASDAQ:QURE) on Friday reported initial six-month follow-up data from the first low-dose cohort in its ongoing Phase 1/2a trial evaluating investigational gene therapy candidate AMT-260 in patients with refractory mesial temporal lobe epilepsy (MTLE). MTLE represents the most prevalent...
06-22 23:51
Ovid Therapeutics to Participate in Upcoming Investor Conferences
Ovid Therapeutics announced that its management will participate in two upcoming investor conferences: the Oppenheimer CNS & Neuro-Muscular Summit on June 10 at 3:45 pm ET and the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference on June 15. Presentations will be available via webcast on the company’s website at investors.ovidrx.com, with an archived replay for 30 days post-event.
06-04 11:00
